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OBJECTIVES: To investigate the usefulness of National Health and Nutrition 
Examination Survey (NHANES) data for exposure estimates. To illustrate its utility, 
the relationship between biomarkers of exposure (serum cotinine) and 
cardiovascular disease (WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol) among current, past, and non smokers was examined using NHANES 
2007-2010. METHODS: Data were obtained from NHANES 2007 to 2010. The study 
sample had 11, 960 respondents who were 21 years and above, answered questions 
on cigarette smoking and had complete laboratory values for their biomarkers 
measurement. The population was categorized as current, past, and non smokers. 
The exposure variable was serum cotinine concentration and the outcome variables 
were serum levels of the biomarkers listed above. Weighted survey linear 
regression was used to estimate the association between cotinine concentration 
and biomarkers levels. We also tested the models for different levels of covariates; 
age, sex, race and body mass index (BMI). RESULTS: The levels of WBC (F-value: 
38.78; P-value: <.0001) and HDL (F-value: 26.43; P-value: <.0001) showed higher 
association with cotinine levels than rest of the biomarkers. The R2for the models 
ranged from 0.039-0.261. Higher levels of WBC and lower levels of HDL were 
observed among current smokers relative to past and non smokers. BMI showed a 
high association with most of the biomarkers. The odds of lower HDL were 
significantly higher for 21-35 years age group relative to the >65 years age group. 
Non-Hispanic blacks had a significantly lower HDL than non-Hispanic whites. 
Females had significantly higher HDL than males. These results were consistent 
with that reported in the literature. CONCLUSIONS: A statistically significant 
association was observed between the biomarker of exposure (serum cotinine) and 
WBC and HDL cholesterol. There were also significant differences in the association 
within the different covariate levels.  
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OBJECTIVES: Administrative claims data are commonly used to study CRC 
treatment patterns and outcomes. We critically review existing algorithms for 
identifying incident CRC cases and disease stage at diagnosis within claims data. 
METHODS: A literature search (1989-2012) using the terms: cancer [ti] AND 
(administrative OR claims) AND (assess [ti] or assessment [ti] or predict [ti] or 
prediction [ti] or identify [ti] or identification [ti] or validate[ti] or validation[ti] or 
agreement[ti] or agree[ti]) identified 76 articles with 27 testing algorithms. Of the 
27, two provided algorithms for identifying incident CRC cases and two 
algorithms identified metastatic CRC at diagnosis. We examine the positive 
predictive value (PPV) of each algorithm and suggest revisions for improving the 
PPV. RESULTS: Setoguchi evaluated four algorithms for identifying CRC patients. 
The first and most restrictive required combinations of ICD-9 and treatment 
codes. The second used two diagnoses within two months, the third combined 
the first and second, and the fourth required one diagnosis. Ramsey used one or 
more ICD-9 codes, the same as Setoguchi algorithm 4. The PPV ranged from 45% 
to 71% for algorithms 4 to 1, respectively. Disease stage algorithms included one 
by Anaya for identifying liver metastases (PPV= 87%) and one by Nordstrom for 
identifying metastatic disease at any site (PPV=80%). CONCLUSIONS: For 
identifying incident CRC patients, we suggest revising Setoguchi algorithm 1 to 
follow the well-tested Nattinger breast cancer algorithm with updates to 
surgical/chemotherapy codes. We also recommend fewer criteria among older 
patients, as PPV is lower for patients less likely to receive aggressive care. For 
disease stage, metastatic disease can be accurately identified with a small set of 
codes, but no studies examined algorithms for identifying CRC stages I-III. We 
recommend adapting the Smith and Shih algorithm for breast cancer disease 
staging to CRC while incorporating the metastatic codes reviewed here.  
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OBJECTIVES: The purpose of this study was to compare the medication 
compliance estimates among a sample of infliximab-treated Crohn’s disease  
(CD) using two separate data sources: medical charts and administrative claims. 
METHODS: A Mid-Atlantic regional health plan provided claims data for their CD 
population during calendar years 2006-2010. Claims were aggregated by 
gastroenterologist tax ID in order to identify providers with the largest CD 
patient panels for recruitment into a chart review study. An electronic case 
report form was developed to aid in the chart data extraction and included fields 
for demographics, anthropometrics, diagnoses, medications, diagnostic tests, 
surgical procedures, treatment dose, administered quantity, and service dates. 
Once captured, both the chart and claims data were used to quantify medication 
treatment compliance over one episode of care. RESULTS: One hundred and 
sixty-one infliximab charts were reviewed and merged with the claims data. 
Dosages and vial counts were unavailable in the claims data; therefore,  
intervals between maintenance infusions were calculated, resulting in a mean 
maintenance interval of 58 days (± 15) per patient. Regarding charts, infusion 
date, dosage, and administered quantity were all available. Approximately 83% 
of infliximab patients had a stable dose of 5 mg/kg over the course of their first 
episode of care, with a mean maintenance interval of 60 days. Dosing 
information from patient charts will be used to estimate dosage from  
claims where charts are not present in an effort to create an algorithm for 
estimating dose from administrative claims only. CONCLUSIONS: Claims  
data were less equipped to estimate biologic treatment compliance, while  
the chart data included many indicators necessary to track biologic dosing 
patterns. However, information from claims augmented charts, and provided 
details on a much larger population of biologic patients, highlighting the 
importance of utilizing both the get a better depiction of treatment, compliance, 
and costs.  
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OBJECTIVES: Administrative claims data are used to study BC treatment patterns 
and outcomes. We critically review existing algorithms for identifying incident 
BC cases and disease stage at diagnosis within claims data. METHODS: A 
literature search (1989-2012) using the terms: cancer [ti] AND (administrative OR 
claims) AND (assess [ti] or assessment [ti] or predict [ti] or prediction [ti] or 
identify[ti] or identification [ti] or validate[ti] or validation[ti] or agreement[ti] or 
agree[ti]) identified 76 articles with 27 testing algorithms. Of the 27, three 
provided algorithms for identifying incident BC cases and four algorithms 
classified BC disease stage at diagnosis. We examine the positive predictive 
value (PPV) of each algorithm and suggest revisions for improving the PPV. 
RESULTS: To identify incident BC, Warren used ICD-9 and treatment codes 
across inpatient and outpatient settings (PPV=80%), Freeman used a logistic 
regression with 36 diagnostic and procedural indicators (PPV=70%), and 
Nattinger used a 4-step process using ICD-9 and treatment codes (PPV=93%). For 
disease stage, the Yuen and Cooper papers used diagnostic codes to distinguish 
regional from distant spread of cancer, with PPVs below 60%. Smith used 
diagnoses, procedures, and medical visits to estimate equations for 
distinguishing stage IV from all other patients and stage III from patients with 
stage I/II. Trade-offs between sensitivity and PPV are made using cut-points from 
the models to classify patients into disease stage. Nordstrom’s algorithm 
identified metastatic disease using three components: a diagnosis code for 
secondary neoplasm OR any metastatic chemotherapy agent OR no G-code for 
non-metastatic disease AND G-code for metastatic disease (PPV=81%). 
CONCLUSIONS: For identifying incident BC, we recommend updating the 
Nattinger algorithm with newer codes and fewer criteria for older patients likely 
to receive less aggressive care. For disease stage, we recommend updating the 
Smith algorithm with additional codes from Nordstrom and testing higher cut-
points to maximize PPV.  
 
PRM56  
OSTEOARTHRITIS IS AN INDEPENDENT RISK FACTOR FOR HIGHER EVENT RATE 
OF MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN HYPERTENSIVE 
PATIENTS – FROM 15-YEAR TAIWAN NHIRD DATABASE  
Syu FK 
Chang Bing Show Chwan Memorial Hospital, Changhua City, Taiwan  
OBJECTIVES: Osteoarthritis and atherosclerosis are both chronic inflammatory 
diseases.However, the association between osteoarthritis and the rate of major 
adverse cardiovascular events (MACEs) has never been reported (check 
literature). METHODS: Using the retrospective, observational, longitudinal study 
design, we evaluate the association between osteoarthritis and the rate of MACEs 
in subjects with essential hypertension retrieved from Taiwan National Health 
Insurance Research Dataset (NHIRD). Patients with HTN and free of pre-defined 
MACEs (MI, stroke, CHF, ESRD and PVD) in the entire course were enrolled as 
control group. In contrast, those with both HTN and OA and free of previous 
MACEs were enrolled as study group. RESULTS: Totally up to 56,607 hypertensive 
patients (aged 30-60 years) without previous MACEs at the first year (in 1996) 
were identified. There were 23,530 (41.6 %) patients with concomitant diagnosis 
of OA. The crude MACE rates were significantly higher in hypertensive patients 
with OA than those without OA (MI: 2.37% vs. 1.64 %, p<0.0001; stroke: 3.90% 
vs.3.33%, p=0.0004; CHF: 1.60% vs.1.37%, p=0.025; PVD: 10.24% vs. 4.36%, p<0.0001, 
respectively), except for ESRD (1.05% vs. 1.33%, p=0.0032). After adjusted for birth 
year and sex, the adjusted ORs (95% confidence interval (CI) and p-values) for 
MACE in patients with both OA and HTN were all significantly higher by the 
relative risk of 3.09 (2.69-3.54, p<0.0001) in MI; 2.47 (2.22-2.75, p<0.0001) in stroke; 
2.40 (2.06-2.79, p<0.0001) in CHF; 1.75 (1.48-2.08, p<0.0001) in ESRD and 4.77 (4.38-
5.19, p<0.0001) in PVD, respectively. CONCLUSIONS: Results from this study 
highlight the MACE (MI, stroke, CHF, ESRD and PVD) rates were significantly 
higher in hypertensive patients with OA than those without it.  
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OBJECTIVES: Frequently, commercial health insurance administrative claims 
databases are considered non-representative of the United States (US) 
population because they reflect only working age individuals, and their 
dependents who are currently employed. If this employment characteristic 
exists, it should be visible when large commercial administrative databases are 
compared against US Census demographic data. METHODS: This study 
compared the HealthCore Integrated Research Database (HIRD) and the 
MarketScan Database against US Demographic data for geographic region, age 
and gender. Age groups and geographic regions were coded to be consistent with 
